384PIncidence of germline BRCA1 and BRCA2 mutations among Filipinos
ANNALS OF ONCOLOGY(2018)
Abstract
Background: The Philippines has the highest reported incidence of breast cancer (BC) in Southeast Asia, with a rate of 47.7 per 100,000 per year. 5 to 10% of BC results from a hereditary predisposition with majority caused by BRCA1/2 mutations, conferring a lifetime risk of 55-85% and 35-60%, respectively. Little is known about the contribution of BRCA mutations to cancer incidence in the Filipino population. Methods: Patients from St. Luke’s Medical Center-Quezon City were enrolled with written informed consent. DNA samples were obtained from a total of 192 subjects (181 females, 11 males; 18-76 years old) who met the National Comprehensive Cancer Network (NCCN) criteria for BRCA genetic testing: 95 had breast cancer (BC), 18 had ovarian cancer, 1 had fallopian tube carcinoma, 4 had concomitant ovarian and BC; 78 had no known cancer diagnosis but with strong family history. Next generation sequencing (NGS) approach for diagnostic mutation screening of the BRCA1/2 gene using the Miseq Illumina platform was performed, followed by confirmation of identified variants by Sanger sequencing. Results: Among 192 patients, 13 (6.77%) were pathogenic, 6 with BRCA1 mutations (2 cases of c.5398delC, 2 cases of c.4148C>G, c.5314C>T, c.2213_2214dupTT) and 7 with BRCA2 mutations (c.3362C>G, 3 cases of c.2176delG, c.8009C>T, 2 cases of c.5851_5854depAGTT). Eight out of 13 patients with pathological variants had breast carcinoma, 1 had DCIS, 1 had ovarian carcinoma, 1 had fallopian tube carcinoma, and 2 were healthy individuals. 10 (5.21%) variants of uncertain significance were identified, which would require further co-segregation analysis. 169 (88.02%) were benign/no pathogenic variant detected. Conclusions: This is the first local study to apply NGS of BRCA1/2 mutation analysis in a Filipino population. This study prompts further investigation of unique variants to enable better understanding of the genetic predisposition to cancer among Filipinos. Benefits of BRCA1/2 mutation testing include optimal treatment tailored for BRCA-positive patients and, more importantly, extending testing to family members and helping them take measures for early detection of cancer. Legal entity responsible for the study: St. Luke's Medical Center-Quezon City. Funding: St. Luke's Medical Center-Quezon City; AstraZeneca. Disclosure: F.V.F. Que: Research funding: Celltrion, MSD Oncology, Pfizer, AstraZeneca. R.W. Lo, M.S. Imasa: Leadership, Stock and other ownership interests: Histosolutions. R.K. Li: Consulting or advisory role: Boehringer Ingelheim, Eisai, Mundipharma; Speakers' bureau: Boehringer Ingelheim, Eisai, Sanofi Research funding, Amgen, Celltrion, MSD Oncology, Novartis, Pfizer. All other authors have declared no conflicts of interest.
MoreTranslated text
Key words
brca2 mutations,germline brca1
AI Read Science
Must-Reading Tree
Example
![](https://originalfileserver.aminer.cn/sys/aminer/pubs/mrt_preview.jpeg)
Generate MRT to find the research sequence of this paper
Chat Paper
Summary is being generated by the instructions you defined